The Pharmacy Times® Zoster Resource Center is a comprehensive resource for clinical news and expert insights on the reactivation of the chickenpox virus in the body, which causes a painful rash.
August 26th 2025
A novel shingles vaccine candidate demonstrated positive topline results of antibody and CD4⁺ T cell vaccine responses.
Though most primary care physicians indicate a willingness to accept expanded recommendations from the Advisory Committee on Immunization Practice suggesting administration of recombinant zoster vaccine for adult patients who are immunocompromised, cost concerns and knowledge gaps limit vaccine delivery.
Read More
2022 CDC, ACIP Updates to Patient Eligibility for Shingles Vaccination
June 16th 2022Unlike the 2022 simplification updates for the hepatitis B and pneumococcal vaccine recommendations, ACIP’s recommendations for patient eligibility for zoster vaccination have become more complicated this year.
Read More
Daily Medication Pearl: Famvir (Famciclovir)
June 6th 2022Famvir, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for adults patients who are immunocompetent with herpes labialis (cold sores); treatment of recurrent episodes of genital herpes; and treatment of recurrent episodes, suppressive therapy of recurrent episodes and herpes zoster (shingles).
Read More
Pfizer, BioNTech Sign New Global Collaboration Agreement for First mRNA-based Shingles Vaccine
January 6th 2022This will be the third collaboration between Pfizer and BioNTech in the infectious diseases field, following the influenza vaccine collaboration in 2018 and the COVID-19 vaccine collaboration in 2020.
Read More